COVID-19 trials registries data warehouse

https://clinicaltrials.gov/show/NCT04715295

Eugene Sobngwi, MD, PhD

sobngwieugene@yahoo.fr

2021-01-20

Unknown

RCT

Randomized

Parallel

Open label

single-center

Treatment

inclusion criteria: - covid-19 infection confirmed by sars-cov2 - rt pcr - as per protocol - able to start the treatment within 24 hours from time of diagnosis - patient with mild symptoms as defined by who, with pao2 > 93% - signed written consent of the patient - accepts and has the ability to be reached by phone during the study duration, plus a designated a contact person who can be contacted in case of emergency

- blood pressure < 90/60mm hg - respiratory rate ≥ 30/min - known cardiac condition - known g6pd deficiency - patients with < 45kg - egfr < 30 ml/min or alt ≥ 3n or body temperature ≥ 38°c or any life-threatening comorbidity - any reason that makes it impossible to monitor the patient during the study period - baseline ecg prior to randomization showing qtc > 500 ms - ongoing treatment other than symptomatic - history of retinopathy - absolute contra-indication to treatment with hydroxychloroquine (known hypersensitivity, concomitant treatment at risk of torsades de pointes) - contraindication to any study medication including allergy - ongoing treatment with high dose systemic chronic corticosteroid (> 40 mg) - patients treated by immunosuppressants treatment at the time of randomization - known pregnant women and breastfeeding women

2

Yaounde Central Hospital

18

100

Cameroon

Mild/moderate disease at enrollment

2: Mild/moderate disease at enrollment

200

Clinical;Virological

None

Phase 4

[{"arm_notes": "", "treatment_id": 1489, "treatment_name": "Doxycycline+rivaroxaban", "treatment_type": "Antibiotics+coagulation modifiers", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2188, "treatment_name": "Standard of care", "treatment_type": "Standard of care", "pharmacological_treatment": "Standard of care"}]